The FDA recorded a supplement to an abbreviated new drug application for generic risperidone from a single manufacturer. This is a manufacturing or labelling supplement to an already-approved generic, not a new indication, a safety communication or a label change that alters how the drug is used.
Risperidone remains a widely used first-line antipsychotic, and nothing in this record changes dosing, monitoring or prescribing. It is included here for completeness of the regulatory record.
The standing per-desk regulatory list holds these decisions with their dates for anyone who wants to trace them.
- The action is an abbreviated new drug application supplement for generic risperidone, not a new approval or indication.
- No label change, safety warning or dosing change accompanies it.
- Risperidone's place in practice is unchanged.
- Treat it as an administrative entry, not clinical news.
Why it matters
It confirms continuity of generic supply rather than signalling any change a prescriber must act on.
Don't overread it
A generic application supplement is an administrative step, not a safety finding or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free